LDS/Medical Tests/Tramadol, Urine

Tramadol, Urine

Tramadol is a synthetic opioid agonist that possesses an analgesic potency similar to that of codeine, but is considered safer (less respiratory effects) and has less potential for abuse. The typical route of administration is oral, although injectable formulations are available. Tramadol is extensively metabolized. Major metabolites include the inactive metabolite nortramadol and the active metabolite O-desmethyltramadol. This metabolite elicits up to four times the analgesic efficacy of the parent drug tramadol and possesses a longer half-life. The primary metabolic enzyme involved in production of O-desmethyltramadol is CYP2D6. The half-life of tramadol is 4.3-6.7 hours.

Approximately 90% of a single oral dose is eliminated in the urine within 72 hours. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: nausea, vomiting, dizziness, headache, somnolence, and constipation. Overdose effects include agitation, hypertension, tachycardia, seizures, respiratory depression, coma, and possible death.

Tramadol can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Tramadol and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC) or Immunoassay (IA). Targeted assays are required to distinguish between tramadol and metabolites. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection. May contribute to a false positive in immunoassays designed to detect phencyclidine (PCP).

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. CYP2D6 is a major route for the activation of tramadol. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.